Cyclopharm Ltd
ASX:CYC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (3.9), the stock would be worth AU$0.96 (32% upside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 3 | AU$0.73 |
0%
|
| 3-Year Average | 3.9 | AU$0.96 |
+32%
|
| 5-Year Average | 3.6 | AU$0.87 |
+20%
|
| Industry Average | 3.3 | AU$0.8 |
+10%
|
| Country Average | 2.7 | AU$0.65 |
-10%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| AU |
C
|
Cyclopharm Ltd
ASX:CYC
|
80.6m AUD | 3 | -4.7 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
171.7B USD | 9.5 | 59.6 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
159.2B USD | 3 | 25.3 | |
| US |
|
Stryker Corp
NYSE:SYK
|
126B USD | 5.6 | 38.8 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
106.8B USD | 2.2 | 23.2 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
96.2B USD | 4 | 33.6 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
41.6B EUR | 2.2 | 19.3 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.3B USD | 4.5 | 43.3 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
46.1B USD | 28.2 | 42.7 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
44.3B USD | 1.8 | 25.2 | |
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
32.5B USD | 3.1 | 15.4 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.6 |
| Median | 2.7 |
| 70th Percentile | 4.3 |
| Max | 2 199.4 |
Other Multiples
Cyclopharm Ltd
Glance View
Cyclopharm Ltd. is a radiopharmaceutical company, which engages in the diagnostic imaging in lung health. The company provides diagnostic imaging services specializing in lung health. The firm through its medical device and pharmaceutical products under the name of Technegas, which has become the industry in diagnostic functional lung imaging technology. The company distributes its products in approximately 60 countries throughout the world with over 1500 nuclear medicine departments utilizing Technegas. The firm formed a joint venture with Alfred Health Solutions and Macquarie University Hospital to provide various imaging services on-site at the hospital. The Macquarie Medical Imaging (MMI) offers a range of diagnostic radiology, interventional radiology, nuclear medicine and molecular imaging services for inpatient and outpatients. Its Ultralute is a device that extends the useful life of Molybdenum-99 (Mo-99) generators.
